Advertisement
"We are very excited to have Malcolm and Tara join Cardiva during thisexciting stage in the company," says Augustine Lien, Chairman and CEO. "Theirexpertise in the medical device industry will be beneficial in the growth ofour company."
Advertisement
Malcolm Farnsworth joined Cardiva in January 2008. Previously, Mr.Farnsworth served as Executive Vice President and Chief Financial Officer atPOINT Biomedical Corporation, a specialty pharmaceutical company developingpharmaceutical imaging agents to detect coronary artery disease. Prior tothat, he served as Vice President of Finance and Chief Financial Officer atGynecare, Inc., a medical device company, that was acquired by Johnson &Johnson after its IPO in 1996. Before that he served as Vice President ofFinance and Chief Financial Officer at Origin Medsystems, a minimally invasivesurgical device company that was acquired by Eli Lilly and merged intoGuidant. Mr. Farnsworth holds an M.B.A. degree from the Haas School,University of California at Berkeley and a B.S. degree in Business andEconomics from Lehigh University.
Tara L. Zerby joined Cardiva in November 2007. Ms. Zerby brings with herover 25 years of experience in sales, marketing and management in the medicaldevice industry. Prior to joining Cardiva, she served as Vice President andGeneral Manager of RTI-Cardiovascular, formerly the Alabama Tissue Center.Ms. Zerby operated her own consulting firm, assisting start-up medical devicecompanies. She was also the executive Director of Marketing and ClinicalApplications for Stereotaxis, Inc., Business Unit Director, Surgical Systemsand Director of Global Sales for Cryocath Technologies. Ms. Zerby holds anM.B.A. from University of Wisconsin, an M.A. from Georgia State and a B.A.from Wake Forest.
About Cardiva Medical, Inc.
Founded in July 2002, and headquartered in Mountain View, Calif.,Cardiva Medical, Inc. is a privately held medical company focused ondeveloping and commercializing vascular access site management and closuredevices with unsurpassed safety and ease-of-use. Cardiva's first product, theBoomerang Wire System, was approved in EU countries and in the US in 2004.Cardiva's second-generation product, the Boomerang Catalyst System, wasapproved in March 2007 and launched in July 2007. The enhanced BoomerangCatalyst, trade named as "Boomerang Catalyst II System" received 510(K)clearance in September 2007 and launched in January 2008. Cardiva was selectedby Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award forEntrepreneurial Company in the U.S. angioplasty and vascular closure devicesmarket. For additional information about Cardiva Medical, Inc. see our websiteat http://www.cardivamedical.com.
Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registeredtrademarks of Cardiva Medical, Inc.Media Contact: Glenn Foy, President Cardiva Medical, Inc. Phone: 650.964.8900, x 215 Fax: 650.964.8911 [email protected]
SOURCE Cardiva Medical, Inc.
